Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A Phase 3 Study Comparing 2 Doses of CP-690,550 vs. Placebo for Treatment of Rheumatoid Arthritis

ClinicalTrials.gov ID: NCT00814307

Public ClinicalTrials.gov record NCT00814307. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 4, 2026, 3:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of CP-690,550 Monotherapy In Patients With Active Rheumatoid Arthritis

Study identification

NCT ID
NCT00814307
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Pfizer
Industry
Enrollment
611 participants

Conditions and interventions

Interventions

  • CP-690,550 Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 31, 2009
Primary completion
May 31, 2010
Completion
May 31, 2010
Last update posted
Jan 17, 2013

2009 – 2010

United States locations

U.S. sites
31
U.S. states
17
U.S. cities
30
Facility City State ZIP Site status
Pfizer Investigational Site Gilbert Arizona 85234
Pfizer Investigational Site Tucson Arizona 85704
Pfizer Investigational Site Hot Springs Arkansas 71913
Pfizer Investigational Site Jacksonville Florida 32216
Pfizer Investigational Site Sarasota Florida 34233
Pfizer Investigational Site Tampa Florida 33614
Pfizer Investigational Site Venice Florida 34292
Pfizer Investigational Site Zephyrhills Florida 33542
Pfizer Investigational Site Rockford Illinois 61107
Pfizer Investigational Site Frederick Maryland 21702
Pfizer Investigational Site Hyannis Massachusetts 02763
Pfizer Investigational Site Kalamazoo Michigan 49048
Pfizer Investigational Site Teaneck New Jersey 07666
Pfizer Investigational Site Albany New York 12206
Pfizer Investigational Site Olean New York 14760
Pfizer Investigational Site Rochester New York 14618
Pfizer Investigational Site Charlotte North Carolina 28210
Pfizer Investigational Site Rocky Mount North Carolina 27803
Pfizer Investigational Site Winston-Salem North Carolina 27103
Pfizer Investigational Site Minot North Dakota 58701
Pfizer Investigational Site Dayton Ohio 45408
Pfizer Investigational Site Bethlehem Pennsylvania 18015
Pfizer Investigational Site Duncansville Pennsylvania 16635
Pfizer Investigational Site West Reading Pennsylvania 19611-1124
Pfizer Investigational Site Greenville South Carolina 29601
Pfizer Investigational Site Myrtle Beach South Carolina 29572
Pfizer Investigational Site Dallas Texas 75231
Pfizer Investigational Site Mesquite Texas 75150
Pfizer Investigational Site Seattle Washington 98104
Pfizer Investigational Site Seattle Washington 98122
Pfizer Investigational Site Clarksburg West Virginia 26301

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 64 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00814307, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 17, 2013 · Synced May 4, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00814307 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →